References
- MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4:58–74
- Witt DM, Lousberg TR. Controversies sur-rounding estrogen use in postmenopausal women. Ann Pharmacother 1997;31: 745–55
- Linzmayer L, Semlitsch HV, Saletu B, et al. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen—progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittel-forschung 2001;51:238–45
- Whitehead MI, Townsend PT, Pryse-Davies J, et al. Actions of progestins on the morphology and biochemistry of the endometrium of postmeno-pausal women receiving low-dose estrogen therapy. Am J Obstet Gynecol 1982;142:791–5
- Ettinger B, Golditch IM, Friedman G. Gyneco-logic consequences of long-term, unopposed estrogen replacement therapy. Maturitas 1988; 10:271–82
- Corson SL, Richart RM, Caubel P, Lim P. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17beta-estradiol and norgestimate on endome-trial histology. Int J Fertil Womens Med 1999; 44:279–85
- Gust MP, Gangar KF, Hillard TC, Whitehead MI. A risk—benefit assessment of estrogen therapy in postmenopausal women. Drug Saf 1990;5:345–58
- Laurent H, Bittler D, Hofmeister H, et al. Synthesis and activities of anti-aldosterones. J Steroid Biochem 1983;19:771–6
- Muhn P, Fuhrmann U, Fritzemeier KH, Krat-tenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311–35
- Pollow K, Juchem M, Elger W, Jacobi N, Hoffman G, Möbus V. Dihydrospirorenone (ZK30595): a novel synthetic progestagen — characterization of binding to different receptor proteins. Contraception 1992;46: 561–74
- Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospir-enone and its natural counterpart progesterone: biochemical profile and antiandrogenic poten-tial. Contraception 1996;54:243–51
- Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21